A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This single-arm study was designed to evaluate the efficacy and safety of oral Xeloda plus
intravenous Avastin as first-line treatment in women with metastatic breast cancer. Patients
received Xeloda 1000 mg/m² orally (PO) twice daily (BID) on Days 1-15, and Avastin 15 mg
intravenously (IV) on Day 1 of each 3-week cycle. The anticipated time on study treatment was
until disease progression or unacceptable toxicity. The target sample size was <100
individuals.